DEA (Diplôme d'Etudes Approfondies), Neurosciences @
Université de Strasbourg
From 1990 to 1993, Dr Griebel was a Ph.D. student in the Department of Psychophysiology at the University Louis Pasteur (Strasbourg, France), and in the Department of Behavioral Pharmacology at Roche (Basel, Switzerland), where he worked on the involvement of the serotonergic system in the modulation of anxiety behaviors in rodents. He then spent two years as
From 1990 to 1993, Dr Griebel was a Ph.D. student in the Department of Psychophysiology at the University Louis Pasteur (Strasbourg, France), and in the Department of Behavioral Pharmacology at Roche (Basel, Switzerland), where he worked on the involvement of the serotonergic system in the modulation of anxiety behaviors in rodents. He then spent two years as a post-doctoral fellow in the Békésy Laboratory of Neurobiology at the Pacific Biomedical Research Centre (Honolulu, USA). This period was spent on the design, and behavioral and pharmacological validation of animal models of anxiety based on defensive behaviors. In 1995, he took up a post-doctoral fellowship at the Department of Psychology (Christchurch, New Zealand), where he performed research on a genetic model of anxiety in mice.
Later in 1995, he entered the CNS Department of Synthélabo (Bagneux, France), as a researcher in Psychopharmacology, where his work involved the evaluation of the effects of new pharmacological agents in various animal models, including anxiety, depression and stress. Later, his work extended to models of schizophrenia, addiction, cognitive functions, sleep, pain, epilepsy and metabolic syndrome. Synthélabo merged with Sanofi in 1999, and in 2002 he became Head of Psychopharmacology in Sanofi-Synthélabo. Two years later, Sanofi-Synthélabo merged with Aventis, and in 2005 he became Global Head of Psychopharmacology in Sanofi-Aventis, leading scientific research groups in France and in the US. Since 2012, he has responsibility for the scientific evaluation of in- and out-licensing opportunities in the neuroscience field for Sanofi and specific projects at the interface of R&D and business development. Dr Griebel has published over 130 articles in peer-reviewed journals, including first-authored reports in Nature Reviews Drug Discovery, PNAS, Biological Psychiatry, Pharmacology and Therapeutics, and several books and book chapters on the pharmacology of psychiatric disorders.
Director, Evaluation & Valorization @ ► Create and maximize value of abandoned Sanofi compounds, in particular but not exclusively in the CNS area, through the establishment of external partnerships with academic and industry for out-licensing purposes and/or proof-of-concept studies.
► Provide expertise for the evaluation of opportunities in the CNS drug discovery area.
► Member of the Externalization Review Board. From April 2015 to Present (9 months) Editor in Chief, Pharmacology Biochemistry & Behavior @ From January 2015 to Present (1 year) Head, Assets Valorization and Opportunities Evaluation @ ► Repositioning of stopped and deprioritized assets, mainly in the neuroscience area, in academic institutes, biotechs or pharma companies.
► Primary source of external innovation for the Unit by creating strong links with academic, advanced research institutions or biotechs to capture emerging technological innovation to support the activities of the Unit and create value for priority projects and initiatives within Sanofi R&D.
► Mainly transverse activity in close collaboration with internal business partners: Patents, Legal and Business Development. From June 2012 to March 2015 (2 years 10 months) Scientific Advisor and Expert, Neuroscience Drug Discovery Research @ ► Overviewed the whole area of the scientific community in psychiatry to identify new trends and tendencies particularly in the discovery and preclinical areas
► Enabled external contacts for opportunities in the CNS/Discovery area
► Worked closely with the Neuroscience Development Unit and CNS Strategic Portfolio Expansion Unit. Integrated marketing and health economy aspects into early CNS/Discovery and Preclinical studies
► Member of the scientific projects selection committee (7 people), which established the scientific priorities and strategies of the unit.
► Managed Psychiatry unit leaders in day-to-day scientific activities From February 2010 to May 2012 (2 years 4 months) Global Head, Psychopharmacology Department @ The department was comprised of 50 scientists, located in France and US.
► Missions: design and implement animal models of CNS diseases, understanding of diseases mechanisms, identification of new targets and characterization of NMEs to treat psychiatric disorders, neurodegenerative diseases, chronic pain, epilepsy and diabetes. Involved in bringing several drugs from discovery into clinical trials (Phase 2/3).
► Member of the CNS Research leadership team.
► Representative of CNS Research in different scientific committees: target selections, project development teams.
► Management of 15 PhDs (including 6 Senior Group Heads and Associate Directors), 35 scientists (Bagneux, Montpellier, Toulouse and Bridgewater). From November 2002 to January 2010 (7 years 3 months) Group Leader, Psychopharmacology Department @ The team was comprised of 12 scientists located in Bagneux and Toulouse, France. From January 2000 to October 2002 (2 years 10 months) Team Leader, Psychopharmacology Department @ The team was comprised of 4 scientists. From February 1996 to December 1999 (3 years 11 months) Principal Scientist, Psychopharmacology Department @ The team was comprised of 3 scientists. From February 1995 to December 1995 (11 months) Post-doctoral fellow @ Supervisor: Prof. R.N. Hughes. From January 1995 to February 1995 (2 months) Post-doctoral fellow @ Békésy Laboratory of Neurobiology. Supervisor: Prof. R.J. Blanchard From October 1993 to December 1994 (1 year 3 months)
Ph.D. thesis, Psychopharmacology @ University Louis Pasteur From 1990 to 1993 DEA (Diplôme d'Etudes Approfondies), Neurosciences @ University Louis Pasteur From 1989 to 1990 1. Maîtrise (M.Sc.), Psychology @ University Louis Pasteur From 1988 to 1989 2. Certificate of Neurophysiology, Animal Physiology @ University Louis Pasteur From 1988 to 1989 Licence (Degree), Psychology @ University Louis Pasteur From 1987 to 1988 DEUG (Diplôme d'Etudes Universitaires et Générales), Psychology @ University Louis Pasteur From 1986 to 1987 Guy Griebel is skilled in: Neuroscience, Animal Models, Pharmacology, Cognition, Psychopharmacology, Drug Discovery, Scientific Editing, Scientific Communication, New Business Development, Psychiatry Research, Scientific Evaluation, Psychopharmacologie, R&D, Pharmaceutical Industry, Biotechnologie
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension